<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02229149</url>
  </required_header>
  <id_info>
    <org_study_id>13011</org_study_id>
    <secondary_id>ML29212</secondary_id>
    <nct_id>NCT02229149</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer</brief_title>
  <official_title>Randomized Phase II Trial of Chemotherapy of Physician's Choice Plus Trastuzumab Versus Chemotherapy of Physician's Choice Plus Trastuzumab Plus Pertuzumab In Women With Pretreated, HER2-Overexpressing Metastatic Breast Cancer (MBC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>US Oncology Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>US Oncology Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase 2 study will seek to determine the effectiveness of chemotherapy&#xD;
      (physician's choice of vinorelbine, taxane [paclitaxel, docetaxel or nab paclitaxel] or&#xD;
      capecitabine) plus trastuzumab vs chemotherapy (physician's choice) plus trastuzumab plus&#xD;
      pertuzumab in women with HER2-overexpressing metastatic breast (MBC) that has been previously&#xD;
      treated with ado-trastuzumab emtansine (T-DM1) in the metastatic setting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current preferred first-line therapy for patients with HER2-overexpressing metastatic&#xD;
      breast cancer (MBC) is a taxane plus trastuzumab plus pertuzumab, based on results from the&#xD;
      CLEOPATRA trial. For patients with disease that has progressed on trastuzumab and a taxane,&#xD;
      ado-trastuzumab emtansine (T-DM1) was recently approved based on results from the EMILIA&#xD;
      trial showing superiority in this setting compared with capecitabine plus lapatinib. However,&#xD;
      the standard for first-line therapy may change again in the near future, when results become&#xD;
      available from the MARIANNE trial, which is evaluating T-DM1 alone or in combination with&#xD;
      pertuzumab as upfront therapy. Two important questions that may be raised by the findings of&#xD;
      this study are whether pertuzumab is effective as second- or later-line therapy following&#xD;
      single-agent T-DM1, and whether pertuzumab administered beyond progression on prior&#xD;
      pertuzumab therapy is of clinical benefit as trastuzumab has been proven to be.&#xD;
&#xD;
      The study will seek to determine the efficacy of chemotherapy (physician's choice of&#xD;
      vinorelbine, taxane [paclitaxel, docetaxel or nab paclitaxel] or capecitabine) plus&#xD;
      trastuzumab vs chemotherapy (physician's choice) plus trastuzumab plus pertuzumab in women&#xD;
      with HER2-overexpressing MBC that has been previously treated with T-DM1 in the metastatic&#xD;
      setting.&#xD;
&#xD;
      We hypothesize that the addition of pertuzumab to trastuzumab plus chemotherapy will improve&#xD;
      median progression-free survival (PFS), compared to trastuzumab plus chemotherapy alone, as&#xD;
      second- or later-line therapy in patients who have received prior T-DM1. Patients will be&#xD;
      stratified according to whether they have received prior pertuzumab versus not. We will also&#xD;
      explore whether continuing treatment with pertuzumab in patients who have been previously&#xD;
      treated with pertuzumab improves PFS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    per Sponsor request&#xD;
  </why_stopped>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">January 2022</completion_date>
  <primary_completion_date type="Actual">January 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>The primary objective of this study is to compare progression-free survival (PFS [also known as time to disease progression]) with the addition of pertuzumab to trastuzumab plus physician's choice of chemotherapy versus trastuzumab plus physician's choice of chemotherapy in patients who have previously received treatment with ado-trastuzumab emtansine (TDM1) for HER2+ metastatic breast cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) in patients (pts) with prior pertuzumab</measure>
    <time_frame>2 years</time_frame>
    <description>To assess PFS with the addition of pertuzumab to trastuzumab plus physician's choice of chemotherapy in patients who have received prior pertuzumab;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) in pts with prior chemotherapy</measure>
    <time_frame>2 years</time_frame>
    <description>To compare median PFS with the addition of pertuzumab to trastuzumab plus physician's choice of chemotherapy in patients who have received 1 vs 2-3 prior chemotherapy regimens for metastatic disease;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with complete and partial responses</measure>
    <time_frame>2 years</time_frame>
    <description>To compare the objective response rates (ORR; complete response [CR] plus partial response [PR]) between the two treatment arms;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>To assess overall survival (OS) in each of the treatment arms;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events and serious adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>To assess the safety of pertuzumab in combination with trastuzumab and physician's choice of chemotherapy (vinorelbine, paclitaxel, nab-paclitaxel, docetaxel, or capecitabine).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Malignant Tumor of the Breast</condition>
  <arm_group>
    <arm_group_label>Triple Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Physician's choice of chemotherapy plus trastuzumab plus pertuzumab&#xD;
trastuzumab, given as a loading dose of 8 mg/kg intravenously (IV, or through the vein) on Day 1 followed by 6 mg/kg IV every 3 weeks thereafter, AND&#xD;
physician's choice of chemotherapy:&#xD;
Vinorelbine 25 mg/m2 IV weekly times 3 with 1 week off; OR&#xD;
Paclitaxel 80 mg/m2 IV weekly times 3 with 1 week off; OR&#xD;
Nab-Paclitaxel 100 mg/m2 IV weekly times 3 with 1 week off; OR&#xD;
Docetaxel 75 mg/m2 IV every 3 weeks; OR&#xD;
Capecitabine 1500 mg by mouth twice a day (PO BID) 14 days on and then 7 days off.&#xD;
AND pertuzumab given as a loading dose of 840 mg IV on Day 1 followed by 420 mg IV every 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Physician's choice of chemotherapy plus trastuzumab&#xD;
trastuzumab, given as a loading dose of 8 mg/kg intravenously (IV, or through the vein) on Day 1 followed by 6 mg/kg IV every 3 weeks thereafter, AND&#xD;
physician's choice of chemotherapy:&#xD;
Vinorelbine 25 mg/m2 IV weekly times 3 with 1 week off; OR&#xD;
Paclitaxel 80 mg/m2 IV weekly times 3 with 1 week off; OR&#xD;
Nab-Paclitaxel 100 mg/m2 IV weekly times 3 with 1 week off; OR&#xD;
Docetaxel 75 mg/m2 IV every 3 weeks; OR&#xD;
Capecitabine 1500 mg PO BID 14 days on and then 7 days off.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Treatment for all patients will consist of trastuzumab, given as a loading dose of 8 mg/kg IV on Day 1 followed by 6 mg/kg IV every 3 weeks thereafter.&#xD;
Patients randomized to the chemotherapy plus trastuzumab arm (without pertuzumab) can receive trastuzumab 6 mg/kg IV every 3 weeks if they are receiving docetaxel or capecitabine on a 3-week cycle, or 4 mg/kg IV every 2 weeks if they are receiving vinorelbine, paclitaxel, or nab-paclitaxel on a 4-week cycle. The loading dose for all patients remains 8 mg/kg.&#xD;
For patients randomized to the chemotherapy plus trastuzumab plus pertuzumab arm, both trastuzumab and pertuzumab need to be administered every 3 weeks regardless of which chemotherapy agent they are receiving.</description>
    <arm_group_label>Double Therapy</arm_group_label>
    <arm_group_label>Triple Therapy</arm_group_label>
    <other_name>Herclon, Herceptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pertuzumab</intervention_name>
    <description>pertuzumab given as a loading dose of 840 mg IV on Day 1 followed by 420 mg IV every 3 weeks.</description>
    <arm_group_label>Triple Therapy</arm_group_label>
    <other_name>2C4</other_name>
    <other_name>Perjeta</other_name>
    <other_name>Omnitarg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine, Paclitaxel, Nab-Paclitaxel , Docetaxel, Capecitabine</intervention_name>
    <description>physician's choice of chemotherapy:&#xD;
Vinorelbine 25 mg/m2 IV weekly times 3 with 1 week off; OR&#xD;
Paclitaxel 80 mg/m2 IV weekly times 3 with 1 week off; OR&#xD;
Nab-Paclitaxel 100 mg/m2 IV weekly times 3 with 1 week off; OR&#xD;
Docetaxel 75 mg/m2 IV every 3 weeks; OR&#xD;
Capecitabine 1500 mg by mouth twice a day (PO BID) 14 days on and then 7 days off.</description>
    <arm_group_label>Double Therapy</arm_group_label>
    <arm_group_label>Triple Therapy</arm_group_label>
    <other_name>Navelbine</other_name>
    <other_name>Abraxane</other_name>
    <other_name>Taxol</other_name>
    <other_name>Taxotere</other_name>
    <other_name>Docecad</other_name>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female, Age ≥ 18 years&#xD;
&#xD;
          2. Histologic or cytologic confirmation of human epidermal growth factor receptor 2&#xD;
             (HER2)-positive breast cancer according to most recent biopsy (local testing&#xD;
             permitted)&#xD;
&#xD;
          3. Measurable or evaluable metastatic disease by Response Evaluation Criteria in Solid&#xD;
             Tumors (RECIST) (v1.1)&#xD;
&#xD;
          4. Previous treatment with ado-trastuzumab emtansine (T-DM1) for metastatic disease&#xD;
&#xD;
             a. Prior therapy with pertuzumab is allowed but not required&#xD;
&#xD;
          5. At least 1 but no more than 3 prior chemotherapy regimens for metastatic breast cancer&#xD;
             (MBC)&#xD;
&#xD;
          6. Life expectancy &gt; 6 months&#xD;
&#xD;
          7. Eastern Cooperative Group (ECOG) performance status ≤ 2&#xD;
&#xD;
          8. Left Ventricular Ejection Fraction (LVEF) ≥ 50% at baseline as determined by either&#xD;
             echocardiogram (ECHO) or Multi Gated Acquisition Scan (MUGA) and within normal limits&#xD;
             per institutional guidelines&#xD;
&#xD;
          9. Adequate bone marrow function as indicated by the following:&#xD;
&#xD;
               1. Absolute Neutrophil Count (ANC) ≥1500/uL (or 1500 per microliter)&#xD;
&#xD;
               2. Platelets ≥100,000/uL&#xD;
&#xD;
               3. Hemoglobin &gt;9 g/dL&#xD;
&#xD;
         10. Adequate renal function, as indicated by creatinine &lt;1.5 times upper limit of normal&#xD;
             (ULN)&#xD;
&#xD;
         11. Adequate liver function, as indicated by bilirubin &lt;1.5 times ULN&#xD;
&#xD;
         12. Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) &lt;2 x ULN unless&#xD;
             liver metastases are present in which case AST and ALT up to 5.x ULN are allowed&#xD;
&#xD;
         13. Negative serum pregnancy test within 72 hours before starting study medications for&#xD;
             women of childbearing potential&#xD;
&#xD;
         14. Women of childbearing potential must be willing to use an acceptable form of birth&#xD;
             control (ie, intra-uterine device, diaphragm with spermicide, condom with spermicide,&#xD;
             or abstinence) for the duration of the study Note: Women are considered postmenopausal&#xD;
             and not of childbearing potential if they have had 12 months of natural (spontaneous)&#xD;
             amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of&#xD;
             vasomotor symptoms), or if they have undergone surgical sterilization.&#xD;
&#xD;
         15. Signed informed consent obtained prior to any screening procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients will be excluded from the study based on the following criteria:&#xD;
&#xD;
          1. Prior treatment in the metastatic setting with the agent chosen as physician's choice&#xD;
             of chemotherapy&#xD;
&#xD;
          2. Active infection&#xD;
&#xD;
          3. Uncontrolled central nervous system metastases, defined as clinical or radiologic&#xD;
             evidence of progression of brain metastases or clinical signs of leptomeningeal&#xD;
             disease&#xD;
&#xD;
             a. Patients with treated brain metastases are eligible provided they do not have&#xD;
             clinical or radiologic evidence of disease progression and have been off of&#xD;
             dexamethasone for at least 3 weeks&#xD;
&#xD;
          4. Patient is pregnant or lactating&#xD;
&#xD;
          5. Prior chemotherapy within the last 3 weeks (last 6 weeks for nitrosureas/mitomycin)&#xD;
&#xD;
          6. Prior radiation therapy within the last 2 weeks; prior radiation therapy to indicator&#xD;
             lesion (unless objective disease recurrence or progression within the radiation portal&#xD;
             has been documented since completion of radiation).&#xD;
&#xD;
          7. Requirement for chronic steroid therapy with a requirement for &gt; 5mg/day of prednisone&#xD;
             or the equivalent.&#xD;
&#xD;
             a. Treatment with physiologic doses of hydrocortisone up to 20 mg daily (QD) is&#xD;
             allowed.&#xD;
&#xD;
          8. Requirement for immunosuppressive therapy, such as those used to treat autoimmune&#xD;
             disease.&#xD;
&#xD;
          9. Concomitant malignancies or previous malignancies within the last 3 years, with the&#xD;
             exception of adequately treated basal or squamous cell carcinoma of the skin or&#xD;
             carcinoma in situ of the cervix.&#xD;
&#xD;
         10. History of significant cardiac disease, cardiac risk factors or uncontrolled&#xD;
             arrhythmias&#xD;
&#xD;
         11. Ejection fraction &lt;50% or below the lower limit of the institutional normal range,&#xD;
             whichever is lower&#xD;
&#xD;
         12. Known hypersensitivity to trastuzumab or pertuzumab&#xD;
&#xD;
         13. Serious medical or psychiatric limitations likely to interfere with participation in&#xD;
             this study.&#xD;
&#xD;
         14. Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs,&#xD;
             resulting in dyspnea at rest or requiring supplemental oxygen&#xD;
&#xD;
         15. Patient is currently part of or has participated in any clinical trial of an&#xD;
             investigational agent within 1 month prior to enrollment in this study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neelima Denduluri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>US Oncology Research, McKesson Specialty Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>19 Sites</name>
      <address>
        <city>Multiple Locations</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>August 27, 2014</study_first_submitted>
  <study_first_submitted_qc>August 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2014</study_first_posted>
  <last_update_submitted>November 29, 2022</last_update_submitted>
  <last_update_submitted_qc>November 29, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>metastatic breast cancer</keyword>
  <keyword>HER2+ breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02229149
org study id: 13011
secondary id: ML29212
nct id: NCT02229149
lead sponsor: 
collaborator: 
has dmc: Yes
This randomized phase 2 study will seek to determine the effectiveness of chemotherapy
      (physician's choice of vinorelbine, taxane [paclitaxel, docetaxel or nab paclitaxel] or
      capecitabine) plus trastuzumab vs chemotherapy (physician's choice) plus trastuzumab plus
      pertuzumab in women with HER2-overexpressing metastatic breast (MBC) that has been previously
      treated with ado-trastuzumab emtansine (T-DM1) in the metastatic setting.
The current preferred first-line therapy for patients with HER2-overexpressing metastatic
      breast cancer (MBC) is a taxane plus trastuzumab plus pertuzumab, based on results from the
      CLEOPATRA trial. For patients with disease that has progressed on trastuzumab and a taxane,
      ado-trastuzumab emtansine (T-DM1) was recently approved based on results from the EMILIA
      trial showing superiority in this setting compared with capecitabine plus lapatinib. However,
      the standard for first-line therapy may change again in the near future, when results become
      available from the MARIANNE trial, which is evaluating T-DM1 alone or in combination with
      pertuzumab as upfront therapy. Two important questions that may be raised by the findings of
      this study are whether pertuzumab is effective as second- or later-line therapy following
      single-agent T-DM1, and whether pertuzumab administered beyond progression on prior
      pertuzumab therapy is of clinical benefit as trastuzumab has been proven to be.

      The study will seek to determine the efficacy of chemotherapy (physician's choice of
      vinorelbine, taxane [paclitaxel, docetaxel or nab paclitaxel] or capecitabine) plus
      trastuzumab vs chemotherapy (physician's choice) plus trastuzumab plus pertuzumab in women
      with HER2-overexpressing MBC that has been previously treated with T-DM1 in the metastatic
      setting.

      We hypothesize that the addition of pertuzumab to trastuzumab plus chemotherapy will improve
      median progression-free survival (PFS), compared to trastuzumab plus chemotherapy alone, as
      second- or later-line therapy in patients who have received prior T-DM1. Patients will be
      stratified according to whether they have received prior pertuzumab versus not. We will also
      explore whether continuing treatment with pertuzumab in patients who have been previously
      treated with pertuzumab improves PFS.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Progression-free survival (PFS)
time frame: 2 years
description: The primary objective of this study is to compare progression-free survival (PFS [also known as time to disease progression]) with the addition of pertuzumab to trastuzumab plus physician's choice of chemotherapy versus trastuzumab plus physician's choice of chemotherapy in patients who have previously received treatment with ado-trastuzumab emtansine (TDM1) for HER2+ metastatic breast cancer.
measure: Progression-free survival (PFS) in patients (pts) with prior pertuzumab
time frame: 2 years
description: To assess PFS with the addition of pertuzumab to trastuzumab plus physician's choice of chemotherapy in patients who have received prior pertuzumab;
measure: Progression-free survival (PFS) in pts with prior chemotherapy
time frame: 2 years
description: To compare median PFS with the addition of pertuzumab to trastuzumab plus physician's choice of chemotherapy in patients who have received 1 vs 2-3 prior chemotherapy regimens for metastatic disease;
measure: Number of patients with complete and partial responses
time frame: 2 years
description: To compare the objective response rates (ORR; complete response [CR] plus partial response [PR]) between the two treatment arms;
measure: Overall survival
time frame: 2 years
description: To assess overall survival (OS) in each of the treatment arms;
measure: Number of adverse events and serious adverse events
time frame: 2 years
description: To assess the safety of pertuzumab in combination with trastuzumab and physician's choice of chemotherapy (vinorelbine, paclitaxel, nab-paclitaxel, docetaxel, or capecitabine).
arm group label: Triple Therapy
arm group type: Experimental
description: Physician's choice of chemotherapy plus trastuzumab plus pertuzumab
trastuzumab, given as a loading dose of 8 mg/kg intravenously (IV, or through the vein) on Day 1 followed by 6 mg/kg IV every 3 weeks thereafter, AND
physician's choice of chemotherapy:
Vinorelbine 25 mg/m2 IV weekly times 3 with 1 week off; OR
Paclitaxel 80 mg/m2 IV weekly times 3 with 1 week off; OR
Nab-Paclitaxel 100 mg/m2 IV weekly times 3 with 1 week off; OR
Docetaxel 75 mg/m2 IV every 3 weeks; OR
Capecitabine 1500 mg by mouth twice a day (PO BID) 14 days on and then 7 days off.
AND pertuzumab given as a loading dose of 840 mg IV on Day 1 followed by 420 mg IV every 3 weeks.
arm group label: Double Therapy
arm group type: Active Comparator
description: Physician's choice of chemotherapy plus trastuzumab
trastuzumab, given as a loading dose of 8 mg/kg intravenously (IV, or through the vein) on Day 1 followed by 6 mg/kg IV every 3 weeks thereafter, AND
physician's choice of chemotherapy:
Vinorelbine 25 mg/m2 IV weekly times 3 with 1 week off; OR
Paclitaxel 80 mg/m2 IV weekly times 3 with 1 week off; OR
Nab-Paclitaxel 100 mg/m2 IV weekly times 3 with 1 week off; OR
Docetaxel 75 mg/m2 IV every 3 weeks; OR
Capecitabine 1500 mg PO BID 14 days on and then 7 days off.
intervention type: Drug
intervention name: Trastuzumab
description: Treatment for all patients will consist of trastuzumab, given as a loading dose of 8 mg/kg IV on Day 1 followed by 6 mg/kg IV every 3 weeks thereafter.
Patients randomized to the chemotherapy plus trastuzumab arm (without pertuzumab) can receive trastuzumab 6 mg/kg IV every 3 weeks if they are receiving docetaxel or capecitabine on a 3-week cycle, or 4 mg/kg IV every 2 weeks if they are receiving vinorelbine, paclitaxel, or nab-paclitaxel on a 4-week cycle. The loading dose for all patients remains 8 mg/kg.
For patients randomized to the chemotherapy plus trastuzumab plus pertuzumab arm, both trastuzumab and pertuzumab need to be administered every 3 weeks regardless of which chemotherapy agent they are receiving.
arm group label: Double Therapy
arm group label: Triple Therapy
other name: Herclon, Herceptin
intervention type: Drug
intervention name: Pertuzumab
description: pertuzumab given as a loading dose of 840 mg IV on Day 1 followed by 420 mg IV every 3 weeks.
arm group label: Triple Therapy
other name: 2C4
other name: Perjeta
other name: Omnitarg
intervention type: Drug
intervention name: Vinorelbine, Paclitaxel, Nab-Paclitaxel , Docetaxel, Capecitabine
description: physician's choice of chemotherapy:
Vinorelbine 25 mg/m2 IV weekly times 3 with 1 week off; OR
Paclitaxel 80 mg/m2 IV weekly times 3 with 1 week off; OR
Nab-Paclitaxel 100 mg/m2 IV weekly times 3 with 1 week off; OR
Docetaxel 75 mg/m2 IV every 3 weeks; OR
Capecitabine 1500 mg by mouth twice a day (PO BID) 14 days on and then 7 days off.
arm group label: Double Therapy
arm group label: Triple Therapy
other name: Navelbine
other name: Abraxane
other name: Taxol
other name: Taxotere
other name: Docecad
other name: Xeloda
criteria: 
gender: Female
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Neelima Denduluri, MD
role: Principal Investigator
affiliation: US Oncology Research, McKesson Specialty Health
facility: 
country: United States
responsible party type: Sponsor
mesh term: Breast Neoplasms
mesh term: Paclitaxel
mesh term: Vinorelbine
mesh term: Docetaxel
mesh term: Capecitabine
mesh term: Trastuzumab
mesh term: Pertuzumab